Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin + Lenvatinib + TACE for Unresectable HCC
NCT05903456Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2023
- Primary completion
- May 2025
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of Icaritin in hepatocellular carcinoma (HCC), sponsored by Zhejiang Cancer Hospital. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
Icaritin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05903456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05903456.